US biotech major Biogen (Nasdaq: BIIB) reported a 7% rise in its second quarter revenue Friday, with sales of $2.45 billion.

At 3:08 p.m. ET (20:08 GMT), the Dow Jones Industrial Average traded 120 points, or 0.3%, the S&P 500 index fell 0.01% after ...

The company has pursued this through costly R&D efforts and acquisitions (e.g., Reata). I rated BIIB a hold and “underperform ...